<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079013</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-7425-AN-CTIL</org_study_id>
    <nct_id>NCT01079013</nct_id>
  </id_info>
  <brief_title>Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies</brief_title>
  <official_title>Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypotheses is that the introduction of dose escalated treosulfan, in substitution
      to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while
      improving disease eradication in patients with lymphoid malignancies not eligible for
      standard transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality</measure>
    <time_frame>2 year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD</measure>
    <time_frame>2 year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>2 year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>treosulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treosulfan</intervention_name>
    <description>12 g/m2 x 3 days</description>
    <arm_group_label>treosulfan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age less than physiologic 68 years.

          2. Patients with NHL and HL with an indication for allogeneic transplantation as follows:

               -  Aggressive lymphoma and Hodgkin lymphoma; relapse after autologous transplants

               -  Follicular lymphoma; failure of at least one prior regimen

          3. Disease must be at chemo-sensitive or stable status to prior therapy before
             transplant.

          4. Patients must have an HLA matched related or unrelated donor willing to donate either
             peripheral blood stem cells or bone marrow. Matching is based on high-resolution class
             I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) typing. The goal is to transplant &gt; 3
             x 106 CD34+ cells per kg body weight of the recipient

          5. Patients must sign written informed consent

          6. Adequate birth control in fertile patients

        Exclusion Criteria:

          1. Overt progressive disease prior to transplantation.

          2. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit

          3. Creatinine &gt; 2.0 mg/dl

          4. ECOG-Performance status &gt; 2

          5. Uncontrolled infection

          6. Pregnancy or lactation

          7. Abnormal lung diffusion capacity (DLCO &lt; 40% predicted)

          8. Severe cardiovascular disease

          9. CNS disease involvement

         10. Pleural effusion or ascites &gt; 1 liter

         11. Known hypersensitivity to fludarabine or treosulfan

         12. Psychiatric conditions/disease that impair the ability to give informed consent or to
             adequately co-operate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

